CD (Suzhou) Biopharma Announces FDA Clearance for Phase I Clinical Trial of CD-001
2024-09-21
CD (Suzhou) Biopharma Co., Ltd.
HaiPress
SUZHOU,China,Sept. 20,2024 --CD (Suzhou) Biopharma has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application of CD-001,entering a Phase I first-in-human trial.
CD-001,the company's leading clinical candidate,is built on its proprietary Bispecific Fusion Protein (BsFP) platform. This potential therapy,designed to target PD-1 positive CD8+ T cells using an anti-PD-1 antibody and engineered IL-21 mutant,aims to address unmet medical needs in oncology and viral infections.
"The FDA's clearance of this IND reinforces our unwavering commitment to advancing groundbreaking immunotherapies." said Dr. Jian Xu,CEO of CD Biopharma. "CD-001 shows promise as a first-in-class and best-in-class treatment,and preclinical studies have demonstrated its effectiveness in various mouse tumor models,with excellent tolerance observed in non-human primates. We are excited to move forward with patient enrollment and expect initial clinical data in the upcoming months."
About CD (Suzhou) Biopharma
Founded in 2021,CD Biopharma is a rapidly advancing clinical-stage biotech company focused on developing innovative therapies across a broad spectrum of immunotherapy areas,including oncology,viral infections,and autoimmune diseases. The company's proprietary Bispecific Fusion Protein (BsFP) platform and IMmune-Enhanced (IME) cell technology,which enable advanced cell modification,continue to drive breakthrough research and clinical outcomes that transform patient care. CD Biopharma is headquartered in Suzhou,with additional research operations in Beijing,China.
For more information,visit https://www.cdbiopharma.com/.
CONTACT:
E-mail: cd@cdbiopharma.com
Newest
-
Se celebra la 68ª sesión de la Comisión de Estupefacientes de las Naciones Unidas: China, un participante activo en la lucha global contra las drogas
-
AXES TREE LLC Launches AXES USDT: Blockchain Meets Advertising
-
Laika Officially Launches the MMS Token Swap Program: Premium Members Unite to Drive a New Market Era
-
"Daily Get·Lottery fund trust services (formerly Cola Financial) and มิราเคิล กรุ๊ป จำกัด reached a strategic cooperation in lottery fund trust to jointly usher in a new era of sunshine in the Asia-Pacific lottery market"